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Abstract
AIM
To assess the prevalence of a panel of serologic markers 
that reflect gut barrier dysfunction in a mixed cohort of 
pediatric and adult primary sclerosing cholangitis (PSC) 
patients.
METHODS
Sera of 67 PSC patients [median age (range): 32 (5-79) 
years, concomitant IBD: 67% and cirrhosis: 20%] 
were assayed for the presence of antibodies against to 
F-actin (AAA IgA/IgG) and gliadin (AGA IgA/IgG)] and 
for serum level of intestinal fatty acid-binding protein 
(I-FABP) by ELISA. Markers of lipopolysaccharide (LPS) 
exposure [LPS binding protein (LBP)] and various anti-
microbial antibodies [anti-OMP Plus IgA and endotoxin 
core IgA antibody (EndoCAb)] were also determined. 
Poor disease outcome was defined as orthotopic liver 
transplantation and/or liver-related death during the 
follow-up [median: 99 (14-106) mo]. One hundred and 
fifty-three healthy subjects (HCONT) and 172 ulcerative 
colitis (UC) patients were the controls. 
RESULTS
A total of 28.4%, 28.0%, 9% and 20.9% of PSC 
patients were positive for AAA IgA, AAA IgG, AGA IgA 
and AGA IgG, respectively. Frequencies of AAA IgA and 
AAA IgG (P  < 0.001, for both) and AGA IgG (P  = 0.01, 
for both) but not AGA IgA were significantly higher 
compared to both of the HCONT and the UC groups. In 
survival analysis, AAA IgA-positivity was revealed as an 
independent predictor of poor disease outcome after 
adjusting either for the presence of cirrhosis [HR = 
5.15 (1.27-20.86), P  = 0.022 or for the Mayo risk score 
(HR = 4.24 (0.99-18.21), P = 0.052]. AAA IgA-positivity was 
significantly associated with higher frequency of anti-
microbial antibodies (P  < 0.001 for EndoCab IgA and 
P  = 0.012 for anti-OMP Plus IgA) and higher level of the 
enterocyte damage marker (median I-FABPAAA IgA pos vs  neg: 
365 vs  166 pg/mL, P  = 0.011), but not with serum LBP 
level. 
CONCLUSION
Presence of IgA type AAA identified PSC patients with 
progressive disease. Moreover, it is associated with 
enhanced mucosal immune response to various microbial 
antigens and enterocyte damage further highlighting the 
importance of the gut-liver interaction in PSC.
Key words: Primary sclerosing cholangitis; Gut barrier 
dysfunction; Intestinal fatty acid-binding protein; Anti-
F-actin antibody; Anti-gliadin antibody
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Core tip: Importance of gut-liver interaction in the 
pathogenesis of primary sclerosing cholangitis (PSC) has 
been certified by a variety of clinical and experimental 
evidences. Clinical manifestations and progression of 
the disease are heterogeneous. No reliable biomarkers 
have been identified to this point that is able to predict 
the pace of progression. In the present, prospective 
follow-up study, we evaluated the clinical importance of 
novel serological markers related to gut barrier function 
in the prediction of progressive disease course in a 
cohort of PSC patients. IgA type anti-F-actin antibody 
was identified as a novel serologic marker during the 
prognostic work-up of PSC. Presence of anti-F-actin IgA 
identified PSC patients with progressive disease course 
and was associated with enhanced mucosal immune 
response to various microbial antigens and enterocyte 
damage further highlighting the importance of the gut-
liver interaction in PSC.
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Orosz P, Szalay F, Lakatos PL, Papp M. Gut barrier failure 
biomarkers are associated with poor disease outcome in patients 
with primary sclerosing cholangitis.World J Gastroenterol 2017; 
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INTRODUCTION
Primary sclerosing cholangitis (PSC) is a chronic cholestatic 
liver disease characterized by persistent, progressive 
biliary inflammation, fibrosis and eventually end-stage 
liver disease. Clinical manifestations and progression of 
the disease are heterogeneous. No reliable biomarkers 
have been identified to this point that able to predict 
the pace of progression. Consequently, patients with 
PSC cannot be stratified properly[1]. 
The etiology of PSC is poorly understood. Importance 
of gut-liver interaction in the pathogenesis of the 
disease however, has been certified by a large body 
of clinical evidence[2]. On the one hand, there is a 
close relation of the disease with inflammatory bowel 
diseases (IBD), up to 80% of the patients have both 
conditions[3]. On the other hand, in PSC patients with 
concomitant IBD, high peritransplant IBD activity 
was associated with higher[4], while colectomy before 
liver transplantation with considerably lower recurrent 
rate of PSC[5]. Experimental findings also supported 
the role of inflamed permeable gut in the subsequent 
inflammation of the biliary tract[6,7]. Patients with 
PSC display an exaggerated immune response to 
intestinal endotoxins with a lack of tolerance to 
repeated endotoxin exposure[8,9]. Prolonged and active 
intestinal inflammation interrupts the gut mucosal 
barrier function with a subsequent endotoxin exposure 
to cholangiocytes. Disruption of cholangiocytes’ tight 
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junctions expose them various substances, such as 
bile acids, that could promote injury and inflammation[3]. 
Disruption of cholangiocytes’ tight junctions is an 
important step in the development of PSC in animal 
models[10,11]. 
Recently, reliable biomarkers of gut barrier function 
have been identified. Concerning enterocyte integrity, 
intestinal fatty acid-binding protein (I-FABP), a 
cytoplasmic protein of enterocytes, was reported as 
marker of enterocyte damage that could be considered 
as the “troponin of the gut”[12]. Anti-F-actin IgA 
antibodies (AAA-IgA) directed against intracellular 
cytoskeletal actin filaments and anti-gliadin IgA 
antibodies (AGA-IgA) serve as the markers of the 
structural intestinal mucosal damage. Presence of 
AAA-IgA strongly correlated with the histological 
findings of total or subtotal small intestinal atrophy in 
patients with celiac disease[13]. Presence of AGA-IgA 
was associated with increased intestinal permeability 
in patients with cirrhosis and significant portal 
hypertension[14].
The aims of this study were to assess: (1) the 
prevalence of a panel of serologic markers that reflect 
gut barrier dysfunction in a mixed cohort of pediatric 
and adult PSC patients; (2) associations between 
these markers and both the clinical and laboratory 
characteristics of the disease; (3) whether serologic 
markers of gut failure is associated with the long-
term disease course in PSC; and (4) association of gut 
failure markers with the markers of lipopolysaccharide 
exposure and mucosal immune reactivity.
MATERIALS AND METHODS
Patient population
We performed an observational cohort study among 
adult and pediatric PSC patients recruited in Hungarian 
referral hepatology centers (Hungarian Autoimmune 
Liver Disease Study Group). In total 67, well-
characterized PSC patients with a complete clinical 
follow-up [adult: 56 (male/female: 40/16), median 
age at presentation: 29 years (IQR: 19-37), median 
disease duration: 6 years (3-12) and children: 11 
(male/female: 8/3), median age at presentation: 10 
years (IQR: 6-12), disease duration: 5 (1-7)] were 
included between January, 2006 and December, 2007. 
Clinical characteristics of patients at enrolment are 
presented in Table 1.
Diagnosis of PSC was based on clinical, biochemical, 
serological and cholangiographic (magnetic resonance 
or endoscopic imaging) features or, when indicated, on 
histological findings[15]. Patients with any concomitant 
malignant disease were excluded. Blood samples 
and detailed description of clinical phenotypes were 
obtained at inclusion. Clinical data were determined 
by thorough review of patients’ medical records, 
which had been collected in a uniform format. Medical 
records that documented disease phenotype (age 
at onset, duration, type of PSC - large duct or small 
duct), presence and type of concomitant IBD, presence 
of overlap syndrome, presence of cirrhosis and portal 
hypertension related complications (e.g., ascites, 
encephalopathy, oesophageal varices or variceal 
bleeding), prior orthotopic liver transplantation (OLTx), 
co-morbidities and medication (e.g., ursodeoxycholic 
acid, steroid, immunosuppressive and/or biological 
therapy) at inclusion were retrospectively analyzed 
for the period prior to the prospective follow-up. At 
enrolment, revised Mayo risk score was calculated[16] 
and biochemical analyses were performed using 
standard routine laboratory protocols for tests including 
platelet count, creatinine, total bilirubin, albumin, 
international normalized ratio (INR) of prothrombin 
time, aspartate aminotransferase (AST), alanine amino-
transferase (ALT), alkaline phosphatase (ALP) and 
γ-glutamyl-transferase (GGT). 
Phenotypical characterization of PSC patients during 
prospective follow-up
Fifty-five out of 67 PSC patients were available to be 
enrolled into a prospective follow-up study, where the 
treating physicians registered laboratory data, imaging 
and endoscopic findings, medical treatment, date and 
type of complications (cirrhosis, colorectal cancer, 
biliary tract cancer: cholangiocarcinoma gallbladder 
cancer or cholangitis) during regular and additional 
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 Patients with PSC (n  = 67)
Age at diagnosis (yr)   25 (17-36)
Disease duration (yr)   6 (3-10)
Children 10 (14.5)
Male 49 (71.0)
Cirrhosis 14 (20.3)
Prior OLTx 4 (5.8)
IBD 52 (75.4)
Crohn's Disease 17 (32.7)
Ulcerative Colitis 35 (67.3)
Overlap syndrome   9 (13.0)
Small duct PSC 5 (7.2)
Celiac disease 1 (1.5)
Albumin (g/L)   44 (40-47)
Bilirubin (μmol/L)   15 (11-22)
ALT (U/L)    52 (26-99)
AST (U/L)    41 (28–66)
GGT (U/L)    152 (60-310)
ALP (U/L)     524 (307-822)
INR       1 (1.0-1.2)
Platelet (109/L)     252 (173-319)
Mayo risk score        -0.595 (-1.194-0.102)
Atypical P-ANCA IgG 57 (85.1)
EMA IgA 1 (1.5)
EMA IgG 1 (1.5)
Table 1  Clinical and laboratory characteristics of primary 
sclerosing cholangitis patients
Data are summarized as median, (interquartile range: 25th-75th percentile) 
or as n (%). ALP: Alkaline phosphatase; ALT: Alanine transaminase; 
AST: Aspartate transaminase; GGT: Gamma glutamyl transferase; INR: 
International normalized ratio; P-ANCA: Perinuclear anti-neutrophil 
cytoplasmic antibodies; EMA: Anti-endomysial antibodies; OLTx: 
Orthotopic liver transplantation; IBD: Inflammatory bowel disease; IQR: 
inter-quartile range.
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Neither bacteria are from the phylum Proteobacteria, 
of which Escherichia coli is a member. The cut-
off for positivity was 25 U as recommended by the 
manufacturer. 
Atypical P-ANCA and anti-endomysial (EMA) 
antibodies were determined by commercially available 
indirect immunofluorescence test (IIF) as a part of the 
differential diagnostic procedure of autoimmune liver 
diseases and celiac disease. Atypical P-ANCA (IgA and 
IgG) and EMA (IgA and IgG) antibody positivities were 
considered in case of specific fluorescencent patterns 
in IIFT (Euroimmun Medizinische Labordiagnostika 
AG, Lübeck, Germany) at a dilution ≥ 1:32 or 1:10, 
respectively as recommended by the manufacturer. 
Detailed description has been reported previously[17,18]. 
Ethical permission
The study protocol was approved by the Regional and 
Institutional Research Ethics Committee of University 
of Debrecen and the National Scientific and Research 
Ethics Committee [DEOEC-RKEB/IKEB 5306-9/2011, 
3515-2011, 3885/2012/EKU (60/PI/2012), 3880/2012/
EKU (59/PI/2012)]. Each patient was informed of the 
nature of the study and gave informed consent in 
writing.
Statistical analysis
Variables were tested for normality using Shapiro Wilk’s 
W test. Continuous variables were summarized as 
medians [interquartile range (IQR, lowest 25%-highest 
25%)] and were compared with the Mann-Whitney U 
test. Categorical variables were compared with χ2 test 
or Fisher’s exact test, as appropriate. We used Kaplan-
Meier analysis to determine association between 
serological antibodies and adverse disease outcome 
(OLTx and/or liver-related mortality). Differences in 
observed survival were assessed by the log-rank test. 
The association of categorical clinical variables or 
serological antibodies with adverse disease outcome 
during the follow-up was evaluated by univariate 
Cox-regression analysis. Multivariate analyses were 
performed to adjust for the Mayo risk score or presence 
of cirrhosis with forced entry method. Associations are 
given as hazard ratio [HR] with 95%CI. For statistical 
analysis and graphical presentation, the SPSS v.22.0 
(SPSS, Chicago, IL, United States) and GraphPad 
Prism 6 (San Diego, CA, United States) programs were 
used. A two-sided probability value of < 0.05 was 
considered to be statistically significant.
RESULTS
Biomarkers of gut barrier function in PSC and their 
association with clinical or laboratory characteristics of 
PSC 
Frequencies of IgA and IgG isotype AAA and AGA in 
PSC and control groups comprising healthy blood-
donors and patients with UC but without PSC are 
summarized in Table 2. A total of 40.3% (27/67) and 
22.4% (15/67) of PSC patients were positive for IgA 
outpatient follow-up visits and inpatient stays. In 
Hungary, a follow-up visit is usually scheduled for 
every 6 mo at a specialized hepatology center (the 
actual interval varies between 3 mo-6 mo). Collected 
data were transferred and stored in a database for 
analysis. On December 1, 2015, all patients’ charts 
and data were reviewed and updated for the data 
points mentioned above. Adverse outcome was 
defined as need for OLTx and/or liver-related death 
(composite end-point). Follow-up for a particular 
patient was terminated if there was no further record 
available or adverse outcome occurred. Cases with 
non-liver related death were censored at the time of 
event. Median follow-up from inclusion was 2646 (IQR: 
401-3130) d. 
Control groups
Healthy controls and patients with ulcerative colitis (UC) 
as disease control group were included.
Healthy control group consisted of 153 individuals 
selected from consecutive blood donors in Debrecen. 
Control subjects did not have any known gastrointestinal 
or liver diseases.
Ulcerative colitis group consisted of a previously 
reported cohort of 172 patients without PSC [male/
female: 79/93, age: 34 (23-44) years][17].
Serological analysis
Blood samples were obtained at enrolment from each 
patient and were frozen at -70 ℃ until testing. All 
the serological assays were performed in a blinded 
fashion without prior knowledge of the patient’s clinical 
information. Commercially available ELISAs were 
used according to the manufacturer’s protocol to 
determine serologic markers of gut barrier function, 
lipopolysaccharide (LPS) exposure and anti-microbial 
antibodies. Positive cut-off levels for individual 
markers were defined either by the manufacturer’s 
recommendation or by the 95th percentile of healthy 
controls and used to dichotomize absolute values. 
Presence of IgA or IgG type antibodies against 
F-actin (AAA) and gliadin (AGA) (QUANTA Lite®; INOVA 
Diagnostics, San Diego, CA) and level of intestinal fatty 
acid-binding protein (I-FABP) (Hycult Biotechnology, 
Uden, Netherlands) were determined as the serologic 
markers of gut barrier function. The cut-off for 
positivity was 35 U and 25 U for both types of AAA and 
AGA, respectively. 
Level of acute phase protein, lipopolysaccharide 
(LPS) - binding protein (LBP) and endotoxin core IgA 
antibody (EndoCAb IgA) (Hycult Biotechnology, Uden, 
Netherlands) were determined as markers of LPS 
exposure. The cut-off for positivity was 195 U/mL for 
EndoCAb IgA. 
Of the classic anti-microbial serologic antibodies, 
anti-OMP Plus antibody (QUANTA Lite®, Inova Diag-
nostics, San Diego, CA, United States) was detected. 
This assay detects IgA antibody against multiple 
bacterial proteins derived from two species of intestinal 
bacteria (one Gram-positive and one Gram-negative). 
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or IgG isotype AAA and AGA, respectively. Antibody 
prevalence was significantly higher compared to either 
that in patients with UC [14.7% (25/170), P < 0.001 
for AAA and 11.6% (20/172), P = 0.042 for AGA] 
or in healthy controls [6.2% (7/113), P < 0.001 for 
AAA and 7.2% (11/153), P = 0.003 for AGA]. AGA 
positivity was mainly IgG isotype (9% vs 20.9%), 
while AAA was of both IgA and IgG isotypes (28.4% vs 
25.4%) and there was no significant overlap between 
IgA and IgG subtypes of the given antibody. Likewise, 
no significant overlap was observed between AAA and 
AGA. Only 10.4% (7/67) PSC patients positive for 
either type of these antibodies had both AAA (IgA or 
IgG) and AGA (IgA or IgG) antibodies.
We analyzed clinical and laboratory characteristics 
of PSC patients according to their antibody status and 
summarized these results in Table 3. AAA antibody 
status according to its immunoglobulin subtypes was 
not associated with gender, younger age at diagnosis, 
presence of cirrhosis, or concomitant IBD. However, 
values of several biochemical laboratory parameters 
and the Mayo risk score that indicate more severe 
disease were significantly higher in the presence of IgA 
isotype of AAA. In case of IgG isotype of AAA, only a 
single association was reported, namely the median 
level of ALP was significantly higher in antibody 
positive cases compared to antibody negative ones 
(715 vs 493 U/L, P = 0.048). Different AGA isotypes, 
however, were not associated with either the clinical 
or the laboratory characteristics of more severe PSC 
phenotype. 
The presence of AAA IgG was higher in patients 
with overlapping autoimmune hepatitis [55.6% (5/9) 
vs 20.7% (12/58), P = 0.040] compared to patients 
without. In contrast, the frequency of AAA IgA was 
not different between the two groups [33.3% (3/9) vs 
27.6% (16/58), P = 0.706]. 
Significance of gut failure markers in the risk of the 
progressive disease course in PSC
Development of colon cancer occurred in two, while 
biliary tract cancer in one patient during the follow-
up period. Nine patients had at least one episode of 
cholangitis. Seven patients underwent OLTx. Five 
patients died due to liver-related complications. 
Composite end-point (OLTx and/or liver-related death) 
occurred in a total of 9 patients. One patient died due 
to acute myocardial infarction, this case was censored 
at time of death.
We analyzed the association of clinical variables 
and the different isotypes of AAA and AGA. 
In Kaplan-Meier analysis, the median time to OLTx 
and/or liver-related death was 578 d (IQR: 212-1112). 
Presence of cirrhosis and increased Mayo risk score 
(pLogRank = 0.040 and < 0.001, respectively), but 
not gender (P = 0.547), age at onset (P = 0.845), 
disease location (P = 0.548) or concomitant IBD (P = 
0.762) were significantly associated with faster disease 
progression.
Positivity for IgA isotype AAA and AGA (pLogRank 
= 0.019 and 0.005, respectively), but not for IgG 
isotypes of these antibodies (pLogRank = 0.665 and 
0.130, respectively) predicted OLTx and/or liver-
related death, see Figure 1. Accordingly, univariate 
Cox regression analysis revealed AAA IgA and AGA 
IgA-positivity as predictors of poor disease outcome 
[HR = 4.54 (1.14-18.18), P = 0.032 and 5.83 
(1.45-23.41), P = 0.013]. Thereafter, we used Cox 
regression analysis to adjust for important clinical 
variables that influence disease progression. Both IgA 
isotype AAA and AGA remained significant predictors 
of disease progression after adjusting for the presence 
of cirrhosis [HR = 5.15 (1.27-20.86), P = 0.022 and 
5.07 (1.25-20.54), P = 0.023, respectively]. Similar 
results, but with weakened statistical significance was 
observed in the case of AAA IgA-positivity [HR = 4.24 
(0.99-18.21), P = 0.052] after adjusting for the Mayo 
risk score, however the significant association was lost 
in case of AGA IgA-positivity [3.67 (0.88-15.30), P = 
0.074].
Role of bacterial translocation and enterocyte damage 
markers in the risk of progressive disease course in 
PSC
As a next step, we analyzed various serological 
markers of bacterial translocation and enterocyte 
PSC (n  = 67) UC (n  = 172) P  value1 HC (n  = 153) P  value1
AAA
IgA 19 (28.4) 19 (11.2)    0.003   5 (4.4) < 0.001
IgG 17 (25.4)  7 (4.1) < 0.001   3 (2.7) < 0.001
IgA or IgG 27 (40.3) 25 (14.7) < 0.001   7 (6.2) < 0.001
IgA and IgG  9 (13.4) 1 (0.6) < 0.001   1 (0.9)    0.001
AGA
IgA  6 (9.0)  6 (3.5)    0.101   4 (2.6)     0.071
IgG 14 (20.9)  15 (8.7)    0.014   9 (5.9)    0.002
IgA or IgG 15 (22.4) 20 (11.6)    0.042 11 (7.2)    0.003
IgA and IgG  5 (7.5)  1 (0.6)    0.007   2 (1.3)    0.029
Table 2  Gut failure markers in patients with primary sclerosing cholangitis and various healthy and diseases control groups n  (%)
1P-values pertain to comparisons between PSC and the given control group. AAA IgA/G was measured in 170 patients with UC and 113 healthy controls. 
PSC: Primary sclerosing cholangitis; UC: Ulcerative colitis; HC: Healthy controls; AAA: Anti-F-actin antibody; AGA: Anti-gliadin antibody.
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of PSC patients. To our knowledge, this is the first study 
examining disease outcomes in PSC according to these 
serological markers[19].
The cytoskeleton protein, F-actin was identified as a 
specific target of smooth muscle cell antibodies (SMA) in 
autoimmune hepatitis[20] and for over a decade IgG isotype 
AAA testing - either by immunofluorescence technique 
or ELISA - has been incorporated into the diagnostic 
procedure of the disease[21]. Increased occurrence of this 
antibody was reported in other autoimmune diseases 
(e.g., celiac disease or connective tissue disease)[22]. To 
our knowledge no previous study assessed, however, 
the prevalence and isotype characteristics of AAAs in 
PSC. 
In the present study, we demonstrated - for the 
first time - that enhanced AAA formation is a feature 
of PSC regardless of overlapping AIH. A quarter of 
our PSC patients showed positivity for AAA that was 
significantly higher compared to either patients with 
UC or healthy controls. Contrary to routine laboratory 
practice, AAA was identified by anti-IgA secondary 
antibody in addition to anti-IgG one. This approach 
revealed isotype dependent association of AAA with 
clinical characteristics of the disease. The presence 
of IgA, but not IgG type AAA indicated more severe 
disease at baseline based on Mayo risk score and 
different biochemical parameters. Concordantly, previous 
studies in celiac disease reported that the presence of IgA 
isotype AAA were strongly associated with the degree of 
active tissue damage of the intestinal mucosa. At the 
same time, AAA IgA-positivity disappeared parallel to 
mucosal healing after gluten free diet was introduced. 
Of note, cases with persistent intestinal mucosa 
damage despite gluten-free diet, remained positive for 
AAA IgA antibody[23].
As a further novel finding of our study, the presence 
of AAA IgA-positivity predicted faster disease progression 
during follow-up, even after adjusting for the presence 
of cirrhosis or the Mayo risk score. We considered both 
liver-related death and OLTx as equal endpoints, since 
they represent the development of end-stage liver 
disease as the result of the progressive fibrosis. 
The mechanism how the breakdown of tolerance 
towards F-actin is associated with the development 
of enhanced fibrosis and thus disease progression in 
the liver remaines to be elucidated. Interestingly, in 
our study patients with positivity for AAA IgA had an 
enhanced mucosal immune response to microbial 
antigens, like endotoxin (EndoCab IgA) or bacterial 
proteins (anti-OMP Plus IgA). This immune response 
seems to be restricted to the intestinal mucosal 
compartment without leading to systemic reaction 
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Figure 1  Progressive disease course in primary sclerosing cholangitis according to the presence of different gut-failure related serological antibodies. 
Patients positive for anti-F-Actin IgA (A) or anti-gliadin IgA (C) have higher cumulative probability of disease progression defined by need for OLTx and/or death 
compared to those negative for these antibodies. IgG isotypes of these antibodies were not associated with progressive disease course (B and D).
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since serum LBP concentration, the serologic hallmark 
of systemic LPS exposure were similar in AAA IgA 
positive and negative cases. This result is in agreement 
with the findings of previous studies. Namely, portal 
venous bacteraemia is not frequent in PSC. However, 
exposure of endotoxins to biliary epithelial cells leads 
to disruption of enterocytes’ and cholangiocytes’ 
tight junctions through TLR4 mediated signaling that 
is an important step in the pathogenesis in animal 
models of PSC[3,24]. Our observation that serum level 
of I-FABP was significantly higher in the group of 
patients with AAA IgA-positivity compared to those 
with AAA IgA-negativity corresponds to these above-
mentioned literature findings. I-FABP is considered 
an accurate marker of enterocyte damage, since it is 
specifically produced by enterocytes and is released 
to systemic circulation in case of cellular injury during 
inflammatory processes.
Autoantibodies are generally not pathogenic in 
PSC, therefore it may be unlikely that the severity of 
biliary injury is driven by humoral factors. Production 
of AAA may reflect, however an enhanced (immune) 
reactivity of lymphocytes towards surrounding tissue 
and/or cellular debris. Of note, AAA is not organ-
specific since they may be present in a wide range 
of immune-mediated diseases other than PSC, as 
mentioned previously. IgG isotype AAA was associated 
with disease activity and poor survival in autoimmune 
hepatitis[25,26]. In the study of Czaja et al[26]patients 
seropositive for AAA were more commonly HLA-
DR3 positive, while seronegative patients had higher 
frequency of HLA-DR4 positivity than healthy subjects. 
In the same study AAA were also associated with 
HLA-B8 positivity. Interestingly, in PSC Wiencke 
et al[27] also demonstrated that HLA-DR3 and B8 
are associated with progressive disease course. 
Conversely, patients with HLA-DR4 do not experience 
an accelerated disease progression, they also have 
a decreased risk for disease recurrence after liver 
transplantation[28,29]. Based on these previous findings 
we speculate that the formation of AAA IgA in PSC 
might reflect a phenotype with distinct immunological 
function and genetic susceptibility for a more severe 
inflammatory process, similarly as in autoimmune 
hepatitis. A recent report on the association between 
autoantibodies, like atypical P-ANCA and HLA status in 
PSC might further support this hypothesis[30]. Hypothetical 
sero-genotype linkage between AAA IgA-positivity 
and more aggressive HLA genotype warrants further 
exploration.
In the present study, occurrence of AGA was 
significantly higher in patients with PSC compared to 
either that in patients with UC or healthy subjects. 
Frequency of AGA IgG/IgA corresponds to the findings 
of Sjöberg et al[31] (22.4% vs 24%). Distinctly only 
IgG but not IgA isotype were more frequent in our 
study. Higher frequency of AGA is observed in various 
disorders, such as celiac disease, neurodegenerative 
diseases, systemic lupus erythematosus and autoimmune 
liver diseases[32-34]. Investigators have attributed the 
formation of these antibodies to an increased uptake of 
peptides from the gut lumen to the intestinal mucosa 
and presence of AGA is considered as a marker of 
a non-specific immune reaction towards a dietary 
peptide. Furthermore, Reiberger et al[14] reported a 
surprisingly high frequency (about 60%) of AGA in 
patients with liver cirrhosis, mainly of alcoholic origin. 
Patients with AGA had higher portal venous pressure 
and increased intestinal permeability assessed by 
the sucrose-lactulose-mannitol test. Nevertheless, 
a Swedish study including 22 patients with PSC 
failed to detect an altered intestinal permeability 
in PSC[35]. Intestinal permeability in PSC might 
rather be considered as an immunological barrier 
dysfunction[8,36]. We found an association between 
IgA type AGA and accelerated disease progression 
in our cohort, however due to the low number of 
positive cases, this finding should be interpreted 
with caution. The increased chance of a false positive 
finding as a result of the small number of positive 
cases is a limitation to be acknowledged. We speculate 
that the finding of an earlier study from a French 
research group might serve as a possible explanation. 
They showed that AGA IgA facilitated an increased 
transport of gliadin peptides from the intestinal lumen 
to the gut mucosa via CD71. In the subepithelial 
space these undigested toxic peptides are able to 
perpetuate intestinal inflammation[37]. Of note, the 
design of our study was mainly explorative and did 
not include experimental methods that could give an 
exact explanation for the increased risk of disease 
progression in the presence of specific antibodies. 
To conclude, we reported that antibodies against 
F-actin are frequent in patients with PSC. Presence 
of IgA isotype of this antibody was associated with 
an enhanced mucosal immune response to various 
microbial antigens and also with the presence of 
enterocyte damage. Furthermore, AAA IgA identified 
a subgroup of patients with an increased risk of 
accelerated disease progression. These results serve 
as additional proof for the importance of the gut-
liver interaction in PSC. If they confirmed in large-
scale cohorts, IgA isotype of AAA could be a candidate 
biomarker for serological risk stratification of patients 
with PSC.
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